BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, has been selected as one of the “50 Smartest Companies in China 2020” (TR50) by MIT Technology Review, a leading technology and business magazine.
Genetron Health was selected for its outstanding performance in the two areas of technological innovation and commercial operations, as well as for its development of precision oncology in China and the U.S. Previous TR50 listed corporations, such as Tesla, Tencent, Apple, IBM Johnson & Johnson, BeiGene, and Wuxi AppTec, are all industry leaders.
Since 2010, MIT Technology Review has published an annual list of the "50 Smartest Companies", lauding companies for their respective technological innovations, business successes, and future potential. The list covers a variety of different fields, such as biotechnology and medical technology, computer and electronics hardware, energy and sustainability, transportation, aerospace, fintech, Internet, optoelectronics, and others. The list reflects the rise of emerging technology companies over the past ten years. It is also one of the most authoritative lists on technology companies in the world, acting as a guide to the future of emerging technologies.
“We are grateful to the MIT Technology Review for its recognition of Genetron Health,” said Mr. Sizhen Wang, co-founder and CEO of Genetron Health. “The mission of Genetron Health is to find the best way to solve the problems of cancer. We use genetic technology to achieve precision oncology treatment in the fields of diagnosis, monitoring, and provide innovative drug research and development services to our partners. We aim to fully meet patients’ needs for personalized diagnosis and treatment, and to promote the clinical application of innovative technology.”
“At the same time, Genetron Health continues exploring ways to eliminate the threat of high cancer mortality,” Wang continued. “We are pleased to have made a series of world-leading breakthroughs in the early detection of cancer using liquid biopsy technology, which helps to make up for the lack of conventional screening methods in terms of accuracy and accessibility. Our technology provides a better method of early screening for more people at high risk of cancer, and leverages innovative technologies to explore new areas of precision oncology. At present, Genetron Health is actively expanding the scope of application of its early screening technology, accelerating the development of its business model, and advancing the process of commercialization. Innovative technologies not only solve major social problems, but also create great commercial value, which is what Genetron Health strives to achieve.”
Genetron Health is a leading precision oncology platform company in China and has built three major business segments, which cover each of the stages of cancer treatment, including early screening, diagnosis and monitoring, as well as biopharmaceutical services. Genetron Health has served more than 500 hospitals and helped doctors diagnose and treat tens of thousands of patients every year. Genetron Health is expanding its biopharmaceutical services business with dozens of domestic and foreign pharmaceutical companies, many of which are engaged to accelerate the development of new drugs.
Under the early screening business segment, Genetron Health has independently developed HCCscreenTM, a liquid biopsy product for the early screening of hepatocellular carcinoma. HCCscreenTM has been granted a Breakthrough Device Designation by the US Food & Drug Administration. Genetron Health joined multiple national key projects covering liver cancer, lung cancer, and digestive system cancer led by China’s Ministry of Science and Technology, and initiated a cohort study involving hundreds of thousands of patients.
The TR50 list is published annually by MIT Technology Review, one of the oldest and most influential media organizations in the technology world. Since 2010, the companies on the list have been selected from around the world on the basis of two core indicators: the companies’ contribution to high-tech innovation, and the success of their business models. To evaluate and select this list of companies, the organizer will invite respected consultants from various related professional fields. They will participate as impartial third party observers, in order to preserve the quality of the companies chosen.
About MIT Technology Review
MIT Technology Review, published by the Massachusetts Institute of Technology starting in 1899, is a technology-focused business magazine and one of the oldest and most influential magazines in the world. The content covers a wide range of topics, including the Internet, communications, computer technology, energy, new materials, biomedicine and business technology. MIT Technology Review’s official Chinese-language website is the only officially authorized website of the MIT Technology Review magazine in China.
MIT Technology Review focuses on the impact of emerging technologies on business and society. It provides forward-looking information and unique, in-depth industry research and analysis for more than 3 million technology professionals and business leaders.
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. To expand the potential applications of cancer molecular profiling technology, Genetron Health also partners with global genomic sequencing technology and instrumentation enterprises, as well as biopharmaceutical companies, to offer customized services and products along the value chain. For more information, please visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.